8-K: Arcturus Reports Q3 2025 Results, Advances Pipeline

Arcturus Therapeutics announced its third quarter 2025 financial results, highlighted by encouraging cystic fibrosis trial data, strategic cost reductions, and a delay in its U.S. COVID-19 vaccine BLA filing.

Summary

• Total revenue for the three months ended September 30, 2025, was $17.2 million, a decrease of $24.5 million compared to the same period in 2024.
• Total revenue for the nine months ended September 30, 2025, was $74.8 million, a decrease of $54.7 million compared to the same period in 2024.
• Net loss for the three months ended September 30, 2025, was $13.5 million, or ($0.49) per diluted share, compared to a net loss of $6.9 million, or ($0.26) per diluted share, in Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $36.7 million, or ($1.35) per diluted share, compared to a net loss of $50.9 million, or ($1.89) per diluted share, in the comparable period of 2024.
• Cash, cash equivalents, and restricted cash totaled $237.3 million as of September 30, 2025, down from $293.9 million on December 31, 2024.
• The cash runway is extended into 2028, supported by additional planned cost reductions in Q4 2025 and the delay of the Phase 3 CF clinical trial commencement until 2027.
• Interim Phase 2 clinical trial data for ARCT-032 in cystic fibrosis showed the 10 mg dose was generally safe and well tolerated, with reductions in mucus burden observed in four of six Class I CF participants after 28 days of treatment.
• The U.S. Biologics License Application (BLA) filing for KOSTAIVE (COVID-19 vaccine) has been indefinitely delayed due to sudden changes in regulatory requirements by the FDA.
• A Phase 1 study of ARCT-2304, a self-amplifying mRNA vaccine candidate for Pandemic Influenza A Virus H5N1, demonstrated robust humoral immune responses after a single dose at all tested levels, further increased by a second dose, with no safety or tolerability concerns.

Sentiment

Score: 4

Explanation: While there are positive clinical developments for pipeline assets and extended cash runway, the significant revenue decline and indefinite delay of a key commercial product's U.S. filing due to regulatory changes weigh heavily on the overall sentiment. The increased Q3 net loss also contributes to a cautious outlook.

Positives

• Encouraging interim Phase 2 data for ARCT-032 in Cystic Fibrosis, showing general safety, tolerability, and reductions in mucus burden in 4 of 6 Class I CF participants.
• Successful Phase 1 study of ARCT-2304 (Pandemic Influenza A Virus H5N1) demonstrating robust immune responses and no safety concerns, validating the STARR sa-mRNA vaccine platform.
• Net loss for the nine months ended September 30, 2025, decreased to $36.7 million from $50.9 million in the comparable period of 2024.
• Cash runway extended into 2028 due to planned cost reductions and delayed Phase 3 CF clinical trial commencement.
• Meiji Seika Pharma launched the two-dose vial of KOSTAIVE updated for the JN.1 variant XEC in Japan after PMDA approval in August 2025.
• Publication of Phase 3 manuscript for ARCT-2303 (COVID-19 vaccine) demonstrating robust immune response and co-administration safety with seasonal influenza vaccine.

Negatives

• U.S. BLA filing for KOSTAIVE (COVID-19 vaccine) indefinitely delayed due to sudden changes in FDA regulatory requirements.
• Revenue for the three months ended September 30, 2025, decreased by $24.5 million compared to the same period in 2024, primarily due to reduced CSL collaboration activity.
• Revenue for the nine months ended September 30, 2025, decreased by $54.7 million compared to the same period in 2024.
• Net loss for the three months ended September 30, 2025, increased to $13.5 million from $6.9 million in the comparable period of 2024.
• Cash, cash equivalents, and restricted cash decreased to $237.3 million as of September 30, 2025, from $293.9 million on December 31, 2024.

Risks

• The likelihood of success of the Company's pipeline (including ARCT-032 and ARCT-810) and partnered programs (including the COVID-19 and flu programs partnered with CSL Seqirus).
• The likelihood that clinical data, including interim data, will be predictive of future clinical results.
• The likelihood that observed mucus plug reduction is predictive of future reduction and will lead to lung function or structural lung defect improvements.
• The likelihood and timing for initiation, and size and scope, of a planned 12-week safety and preliminary efficacy study for ARCT-032.
• The likelihood and timing for achieving alignment with regulatory agencies on pivotal studies for ARCT-810.
• The likelihood of success of any collaboration, including the anticipated continued support from CSL to commercialize KOSTAIVE.
• The continued determination that ARCT-032 is generally safe and well tolerated.
• The likelihood of further development of a self-amplifying mRNA pandemic influenza vaccine candidate.
• The likelihood that preclinical or clinical data will be predictive of future clinical results.
• The impact of general business and economic conditions.
• Risks discussed under the heading "Risk Factors" in Arcturus' most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC.

Future Outlook

Arcturus plans to initiate a 12-week safety and preliminary efficacy study for ARCT-032 in CF patients in the first half of 2026 and aims to achieve alignment with regulatory agencies on pivotal studies for ARCT-810 in OTC deficiency in the first half of 2026. General and administrative expenses are expected to continue to decrease slightly over the next twelve months. The cash runway is extended into 2028, supported by planned Q4 2025 cost reductions and the delay of the Phase 3 CF clinical trial until 2027. The company anticipates continued support from CSL to commercialize KOSTAIVE in Asia and Europe.

Management Comments

• "We were pleased to share the initial findings of ARCT-032 clinical activity with the CF community last month at the NACFC. Conversations at NACFC with CF patients, physicians, investigators and global experts reinforced our commitment to advance ARCT-032 further into development. We look forward to initiating a 12-week safety and preliminary efficacy study in first half of 2026." Joseph Payne, President & CEO.
• "Our team is also working diligently to achieve alignment with regulatory agencies regarding pivotal studies of ARCT-810 in adults and young children with OTC deficiency." Joseph Payne, President & CEO.
• "The observed mucus plug reduction after 28 days of treatment with ARCT-032 in people with Class I CF is encouraging. Clearance of mucus suggests that treatment with ARCT-032 is acting on the thick mucus defect which is fundamental in CF; more extended treatment with ARCT-032 could provide further reduction in mucus burden leading to more meaningful benefits, including lung function and structural lung defect improvement. These changes could ultimately lead to reduction in exacerbations and change the clinical course of this progressive disease." Denis Hadjiliadis, MD, MMHS, FRCP(C), Professor and Cystic Fibrosis Program Director, Perelman School of Medicine, University of Pennsylvania.
• "The sudden changes in regulatory requirements by the FDA for COVID-19 vaccines have delayed the U.S. BLA filing for KOSTAIVE indefinitely. We have decided to reduce additional expenses to extend the runway for the CF and OTC deficiency programs. We anticipate continued support from CSL to commercialize KOSTAIVE in Asia and Europe and will provide more details on our year end call." Andy Sassine, CFO.

Industry Context

The indefinite delay of the U.S. BLA filing for KOSTAIVE due to sudden FDA regulatory changes for COVID-19 vaccines highlights the dynamic and unpredictable nature of vaccine development and approval, particularly in a post-pandemic environment. This could reflect broader challenges faced by vaccine developers in adapting to evolving regulatory landscapes. The continued progress in mRNA therapeutics for rare diseases like CF and OTC deficiency, alongside successful pandemic influenza vaccine development, underscores the growing potential and versatility of mRNA technology in the pharmaceutical industry, positioning Arcturus as a key player in this innovative space despite regulatory hurdles in specific markets.

Comparison to Industry Standards

• The observed mucus plug reduction with ARCT-032 in Class I CF participants is a promising early indicator, as mucus clearance is a fundamental goal in CF treatment. This aligns with the therapeutic objectives of established CF treatments like CFTR modulators (e.g., Trikafta by Vertex Pharmaceuticals), which aim to improve lung function by addressing the underlying defect and reducing mucus burden. While ARCT-032 is an mRNA therapeutic, its mechanism targets a similar outcome, and further extended treatment data will be crucial for direct comparison.
• The successful Phase 1 results for ARCT-2304, a self-amplifying mRNA pandemic influenza vaccine candidate, demonstrating robust immune responses comparable to or higher than MF59-adjuvanted pandemic vaccines, positions Arcturus favorably in the competitive landscape of influenza vaccine development. Companies like Moderna and Pfizer/BioNTech are also advancing mRNA-based influenza vaccines, and Arcturus' STARR platform shows competitive immunogenicity.
• The indefinite delay of the U.S. BLA filing for KOSTAIVE due to "sudden changes in regulatory requirements by the FDA for COVID-19 vaccines" indicates a significant regulatory challenge. This contrasts with the relatively smoother regulatory pathways seen for initial COVID-19 vaccines from companies like Pfizer/BioNTech and Moderna, suggesting a tightening or shifting landscape for subsequent vaccine approvals, especially for new variants or platforms.

Stakeholder Impact

• Shareholders: Potential negative impact due to delayed U.S. commercialization of KOSTAIVE and increased Q3 net loss, offset by extended cash runway and positive pipeline progress which could drive future value.
• Patients (CF, OTC deficiency): Positive outlook due to continued advancement of ARCT-032 and ARCT-810, offering hope for new therapeutic options.
• Employees: Potential impact from planned additional cost reductions, though specific details are not provided.
• Partners (CSL Seqirus, Meiji Seika Pharma): Continued collaboration for KOSTAIVE in Asia and Europe, but U.S. regulatory hurdles may affect broader commercial strategy.
• Regulatory Authorities (FDA): The company is working to achieve alignment with regulatory agencies for ARCT-810 and faced "sudden changes in regulatory requirements" for KOSTAIVE, indicating ongoing engagement and adaptation to evolving standards.

Next Steps

• Initiate a 12-week safety and preliminary efficacy study for ARCT-032 in up to 20 CF participants in the first half of 2026.
• Achieve alignment with regulatory agencies on pivotal studies for ARCT-810 in adults and young children with OTC deficiency in the first half of 2026.
• Enroll subjects in the third cohort of the Phase 2 clinical trial of ARCT-032 (15 mg dose daily over 28 days).
• Implement additional cost reductions in Q4 2025.
• Provide more details on KOSTAIVE commercialization support from CSL during the year-end call.
• Further develop a self-amplifying mRNA pandemic influenza vaccine candidate (ARCT-2304).

Key Dates

Recommendation

The indefinite delay of the U.S. BLA filing for KOSTAIVE is a significant negative, impacting near-term revenue potential from a key commercial product. While the company has extended its cash runway and shown promising early clinical data for ARCT-032 and ARCT-2304, these are still in earlier stages of development and face inherent clinical and regulatory risks. The revenue decline and increased Q3 net loss also warrant caution. The stock is a 'hold' as the long-term potential of its mRNA pipeline for rare diseases and vaccines is compelling, but the immediate commercial setback and ongoing development risks suggest waiting for more definitive progress and regulatory clarity before a stronger recommendation.

Keywords

Arcturus Therapeutics, ARCT, mRNA, Cystic Fibrosis, CF, Ornithine Transcarbamylase Deficiency, OTC deficiency, COVID-19 vaccine, Influenza vaccine, ARCT-032, ARCT-810, KOSTAIVE, ARCT-2304, sa-mRNA, LUNAR, STARR, Biotechnology, Pharmaceuticals, Clinical Trials, Financial Results, Q3 2025, SEC filing